BeiGene inks $60M li­cens­ing, re­search pacts with Zymeworks; Mer­ck, Ab­b­Vie, Am­gen back neu­ro up­start

→ The savvy deal­mak­ers at Zymeworks $ZYME have scored an­oth­er heavy­weight part­ner as BeiGene signs on for re­gion­al rights to two of its ear­ly-stage as­sets and the op­por­tu­ni­ty to de­vel­op three more on its an­ti­body plat­forms.

Be­tween two li­cens­ing deals, the Chi­nese can­cer drug­mak­er $BGNE is pay­ing $60 mil­lion in cash and ded­i­cat­ing up to $1.09 bil­lion col­lec­table at var­i­ous stops of the long de­vel­op­ment and com­mer­cial­iza­tion path.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.